Clinical Trials | June 14, 2026
Breakthrough approval in prostate cancer for AstraZeneca therapy
The decision was driven by results from the Phase III CAPItello-281 trial,
The decision was driven by results from the Phase III CAPItello-281 trial,
First immunotherapy combination approved in the US for BCG-naïve high-risk NMIBC demonstrates a 32% reduction in the risk of disease recurrence, progression, or death
While overall survival data remain immature, the results pointed to a favourable trend.
The study tracked patients for more than five years (median 60.7 months), with protection against disease returning emerging in under four months and continuing long term
The filing is backed by results from the pivotal SERENA-6 Phase III trial
Clearance marks major shift beyond chemotherapy
The recommendation is powered by blockbuster results from the pivotal Phase III SERENA-6 trial
Across more than 85 abstracts, AstraZeneca will showcase 10 approved medicines and 13 potential new therapies
AstraZeneca highlighted the move as a major step toward earlier intervention in curable disease
The facility combines advanced diagnostics, bone marrow transplant evaluation, prenatal awareness, and multidisciplinary support services
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
